Association of Occipital Amyloid PET Burden with ARIA‐E: Exploratory Analyses in Three Clinical Trials of Donanemab
Elevated occipital amyloid burden at baseline was statistically significantly associated with risk of ARIA-E in donanemab-treated participants with early symptomatic AD. The potential of occipital burden to predict ARIA-E should be further validated with additional methodologies, subgroup analyses, and datasets.
Authors
- Sergey Shcherbinin (ORCID: https://orcid.org/0009-0003-9451-1230)
- Ian Andrew Kennedy (ORCID: https://orcid.org/0000-0003-2684-1935)
- Mark A. Mintun
- John Randall Sims (ORCID: https://orcid.org/0009-0009-5090-7886)
- Emily C. Collins
- Ming Lu
- Min Jung Kim
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70862_110828
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00